EpicentRx begins Phase 3 REPLATINUM study of lead program RRx-001 in Small Cell Lung Cancer

Minimally toxic therapies for innate and adaptive immunity against cancer.

Toxicity to Tumors not to Patients

 

EpicentRx is developing new mechanisms of immunotherapy that act alone or in combination with other medicines to outsmart cancer with minimal toxicity across diverse patient populations and tumor types.

IGNITE Platform

EpicentRx’s lead program is RRx-001, a next generation small molecule immunotherapeutic in the Phase 3 REPLATINUM trial to treat small cell lung cancer.

Oncolytic Virus Platform

EpicentRx is developing the first ever series of oncolytic viruses tailored to tumors of individual patients.